Skip to main content
Log in

Exemestane

A Review of its Use in Postmenopausal Women with Breast Cancer

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Abstract

Exemestane (Aromasin®) is an orally active steroidal irreversible inactivator of the aromatase enzyme indicated as an adjuvant treatment in postmenopausal women with estrogen receptor-positive early-stage breast cancer following 2–3 years of adjuvant treatment with tamoxifen, and for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen or other antiestrogen therapy.

Exemestane is effective for the treatment of postmenopausal women with early-stage or advanced breast cancer. In early-stage disease, switching to exemestane for 2–3 years after 2–3 years of adjuvant tamoxifen treatment was more effective in prolonging disease-free survival than continuing tamoxifen therapy, although it was not associated with an overall survival benefit, except in those with estrogen receptor-positive or unknown receptor status disease when nodal status, hormone replacement therapy (HRT) and chemotherapy use were adjusted for. Moreover, preliminary data suggest that the efficacy of exemestane is generally no different to that of tamoxifen in the primary adjuvant treatment of early-stage breast cancer, although exemestane may be better in prolonging the time to distant recurrence. In advanced disease, exemestane showed equivalent efficacy to megestrol in patients with disease refractory to tamoxifen and an efficacy not significantly different from that of fulvestrant in those refractory to a nonsteroidal aromatase inhibitor. Available data, some of which are limited, suggest exemestane is also effective in the first-line hormonal treatment of advanced breast cancer in postmenopausal women. Exemestane is generally well tolerated, although the potential bone fracture risk of the drug requires further investigation. Results from directly comparative trials indicating the efficacy, tolerability and bone fracture risk of exemestane relative to third-generation aromatase inhibitors and other agents in both early-stage and advanced disease, as well as the optimal sequence of endocrine therapies, are awaited with interest. In the meantime, switching to exemestane should be considered in postmenopausal women who have received 2–3 years of adjuvant tamoxifen treatment for early-stage breast cancer, and is an emerging treatment option for postmenopausal women with advanced breast cancer refractory to one or more antiestrogen therapies.

Pharmacological Properties

Exemestane acts by irreversibly binding to the aromatase active site, resulting in potent suppression of whole body aromatization and estrogen synthesis, without any marked or clinically relevant effect on levels of other steroid hormones. The drug may affect lipid levels and increase levels of homocysteine, but does not appear to have long-term effects on coagulation parameters. A switch from tamoxifen to exemestane may also reverse the endometrial thickening associated with tamoxifen. Exemestane is generally associated with a loss of bone mineral density and increases in serum or urinary levels of markers of bone turnover in postmenopausal women.

The absorption of exemestane is rapid after oral administration, with maximum plasma concentrations reached within 2 hours of a single 25 mg dose. The drug is 90% plasma protein bound and is extensively distributed into tissues. Exemestane undergoes extensive metabolism, primarily via cytochrome P450 3A4, as well as via aldoketoreductases, to metabolites that are inactive or have less activity than the parent drug. Exemestane is excreted mainly via urine and faeces and has a mean terminal elimination half-life of ≈24 hours.

Therapeutic Efficacy

Oral exemestane 25 mg/day for 2–3 years after 2–3 years of adjuvant tamoxifen was generally more effective than 5 years of continuous adjuvant tamoxifen in the treatment of postmenopausal women with early-stage estrogen receptor-positive/unknown receptor status breast cancer in a large well designed trial (IES). Switching from tamoxifen to exemestane was consistently associated with a significantly lower risk of experiencing one of the events (recurrence, contralateral breast cancer or death without recurrence) in the primary combined endpoint of disease-free survival than continued tamoxifen at median follow-ups of 30.6 and 55.7 months. The exemestane regimen was also more effective with regard to other endpoints, including the risk of contralateral breast cancer and breast cancer-free survival. There was generally no overall survival benefit in switching to exemestane, except in patients with estrogen receptor-positive or unknown receptor status disease at the median 55.7-month follow-up, when nodal status, HRT and chemotherapy use were adjusted for.

Moreover, preliminary data from the large, randomized, open-label, phase III, TEAM trial comparing exemestane with tamoxifen indicate that exemestane 25 mg/day is also effective in the primary adjuvant treatment of early-stage breast cancer in postmenopausal women. Disease-free survival (primary endpoint) did not significantly differ between exemestane and tamoxifen recipients. There was also no difference between the treatments in terms of relapse-free survival; however, exemestane was more effective in terms of the risk of distant metastases.

Exemestane 25 mg/day has also demonstrated efficacy in the treatment of postmenopausal women with advanced breast cancer refractory to one or more antiestrogen therapies in two large, well designed, phase III studies. In one of these studies, exemestane provided similar efficacy to megestrol in terms of objective response rate (primary endpoint) in postmenopausal women with advanced breast cancer refractory to tamoxifen. Although there was also no significant difference between the treatments in the median duration of objective response or the rate of overall success, exemestane recipients had a significantly longer median duration of overall success, time to disease progression and time to treatment failure than megestrol recipients. In the other trial, exemestane demonstrated efficacy not significantly different from that of intramuscular fulvestrant in patients with advanced breast cancer refractory to a nonsteroidal aromatase inhibitor, with no significant between-group difference in the time to disease progression (primary end-point) or other endpoints, including objective response rate, clinical benefit rate or overall survival.

Data, some of which are limited, from randomized, open-label, phase II or III studies comparing exemestane with anastrozole or tamoxifen, respectively, suggest that exemestane is an effective first-line hormonal treatment in postmenopausal women with advanced breast cancer. There were generally no differences between exemestane and these agents in terms of efficacy, although a significantly higher objective response rate was seen with exemestane than with tamoxifen in the largest phase III study.

Tolerability

Exemestane was generally well tolerated in postmenopausal women with early-stage or advanced breast cancer, with adverse events generally being mild to moderate in severity and of a similar nature irrespective of the stage of disease. Overall, hot flashes were the most common adverse event considered to be drug-related or of indeterminate cause experienced by exemestane recipients in active comparator-controlled trials.

In the large IES, at a median 55.7-month follow-up, patients with early-stage breast cancer switched to exemestane had significantly fewer serious gynaecological events, endometrial hyperplasia, uterine polyps/fibroids, venous thrombolytic events and muscle cramp than those who continued tamoxifen treatment. In contrast, exemestane was associated with a significantly higher incidence of musculoskeletal pain, arthralgia, diarrhoea, carpal tunnel syndrome, paraesthesia and joint stiffness than tamoxifen. There were no between-group differences in the incidences of the most common adverse events: menopausal symptoms (e.g. hot flashes), hypertension and fatigue. Moreover, a switch to exemestane was associated with a significantly lower incidence of abnormal endometrial thickening than continued tamoxifen. Preliminary data from the TEAM study after 2.75 years’ treatment indicated that the tolerability profile of exemestane versus tamoxifen in the primary adjuvant treatment of early-stage breast cancer was generally consistent with the findings of the IES. The incidence of fractures did not significantly differ between exemestane and tamoxifen recipients in the TEAM trial or in an on-treatment analysis of the IES, although it was significantly greater in exemestane than tamoxifen recipients in the IES when post-treatment adverse events were included.

Exemestane also had a generally similar tolerability profile to that of tamoxifen when used as a first-line hormonal treatment in postmenopausal women with advanced breast cancer, although it appeared to be more favourable than tamoxifen in terms of anaemia, thrombocytopenia and vaginal discharge, and less favourable in terms of weight gain, arthralgias, hypertension and diarrhoea (all between-group differences in incidence ≥5%). Postmenopausal women with advanced breast cancer who received exemestane were less likely to experience dyspnoea or moderate to severe gains in body-weight than those who received megestrol, although they were more likely to experience hot flashes, nausea and vomiting. The tolerability profile of exemestane was broadly similar to that of fulvestrant in postmenopausal women with advanced breast cancer.

Pharmacoeconomic Analyses

In modelled cost-utility analyses that incorporated data from the IES and direct medical costs, switching to exemestane after 2–3 years of tamoxifen was generally predicted to be cost effective with regard to the cost per quality-adjusted life-year (QALY) gained relative to continuing tamoxifen treatment in postmenopausal women with early-stage breast cancer in a number of countries over 10-year, 20-year and/or lifetime time horizons. Using data from trials that did not directly compare the regimens, analyses in Canada and Belgium suggested that switching from tamoxifen to exemestane was cost saving in terms of the cost per QALY gained relative to primary adjuvant anastrozole or extended adjuvant therapy with tamoxifen followed by letrozole in postmenopausal women with early-stage breast cancer over a time horizon of 20 years.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Fig. 1
Table IV
Fig. 2
Fig. 3
Table V

Similar content being viewed by others

References

  1. American Cancer Society. Global cancer facts and figures 2007 [online]. Available from URL: http://www.cancer.org/downloads/STT/Global_Cancer_Facts_and_Figures_2007_rev.pdf [Accessed 2008 Jul 30]

  2. Travis RC, Key TJ. Oestrogen exposure and breast cancer risk. Breast Cancer Res 2003 Jul 28; 5(5): 239–47

    Article  PubMed  CAS  Google Scholar 

  3. Foster PA. Steroid metabolism in breast cancer. Minerva Endocrinol 2008 Mar; 33(1): 27–37

    PubMed  CAS  Google Scholar 

  4. Suzuki T, Miki Y, Nakamura Y, et al. Sex steroid-producing enzymes in human breast cancer. Endocr Relat Cancer 2005 Dec; 12(4): 701–20

    Article  PubMed  CAS  Google Scholar 

  5. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Eng J Med 2003 Jun 12; 348(24): 2431–42

    Article  CAS  Google Scholar 

  6. Rugo HS. The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors. Annal Oncol 2008 Jan; 19(1): 16–27

    Article  CAS  Google Scholar 

  7. Pharmacia Ltd. Aromasin® 25 mg coated tablets: summary of product characteristics [online]. Available from URL: http://www.emc.medicines.org.uk [Accessed 2009 Mar 13]

  8. Pharmacia and Upjohn Co. Aromasin® exemestane tablets: US prescribing information [online]. Available from URL: http://www.pfizer.com/files/products/uspi_aromasin.pdf [Accessed 2009 Apr 28]

  9. Moen MD, Wagstaff AJ. Exemestane: a review of its use as adjuvant treatment for early breast cancer in postmenopausal women. Am J Cancer 2006; 5(4): 259–72

    Article  CAS  Google Scholar 

  10. Clemett D, Lamb HM. Exemestane: a review of its use in postmenopausal women with advanced breast cancer. Drugs 2000 Jun; 59(6): 1279–96

    Article  PubMed  CAS  Google Scholar 

  11. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007 Feb 17; 369(9561): 559–70

    Article  PubMed  CAS  Google Scholar 

  12. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Eng J Med 2004 Mar 11; 350(11): 1081–92

    Article  CAS  Google Scholar 

  13. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol 2000 Apr; 18(7): 1399–411

    PubMed  CAS  Google Scholar 

  14. Aihara T, Hozumi Y, Suemasu K, et al. The effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: preliminary results of N-SAS (National Surgical Adjuvant Study) BC04, the TEAM Japan sub-study [abstract no. 2086]. Breast Cancer Res Treat 2007 Dec; 106 Suppl. 1: 114. Plus poster presented at the 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13–16; San Antonio (TX)

    Google Scholar 

  15. van Nes JGH, Papapoulos SE, Braun JJ, et al. Effect of exemestane on bone turnover markers and bone mineral density (BMD): 2 year results of the Dutch/Belgian Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial [abstract no. 1154]. Cancer Res 2009 Jan 15; 69 (2 Suppl.): 152s

    Google Scholar 

  16. McCaig FM, Renshaw L, Williams L, et al. A randomized study of the effects of anastrozole (A), letrozole (L) and exemestane (E) on bone turnover [abstract no. 1145]. Cancer Res 2009 Jan 15; 69 (2 Suppl.): 149s

    Google Scholar 

  17. Coleman RE, Banks LM, Girgis S, et al. Reversal of skeletal effects of endocrine treatments in the intergroup study [abstract no. 1128]. Cancer Res 2009 Jan 15; 69 (2 Suppl.): 144s

    Google Scholar 

  18. McCaig FM, Renshaw L, Williams L, et al. A randomised study comparing the effects of anastrozole (A), letrozole (L), exemestane (E) and tamoxifen (T) on coagulation [abstract no. 1132]. Cancer Res 2009 Jan 15; 69 (2 Suppl.): 145s

    Google Scholar 

  19. Bertelli G, Hall E, Ireland E, et al. Endometrial status in the Intergroup Exemestane Study up to 2 years post-treatment [abstract no. 2078]. Breast Cancer Res Treat 2007 Dec; 106 Suppl. 1: 111. Plus poster presented at the 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13–16; San Antonio (TX)

    Google Scholar 

  20. Wang X, Chen S. Aromatase destabilizer: novel action of exemestane, a food and drug administration-approved aromatase inhibitor. Cancer Res 2006 Nov 1; 66(21): 10281–6

    Article  PubMed  CAS  Google Scholar 

  21. Lønning PE, Geisler J, Krag LE, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005 Aug 1; 23(22): 5126–37

    Article  PubMed  Google Scholar 

  22. Montagnani A, Gonnelli S, Cadirni A, et al. The effects on lipid serum levels of a 2-year adjuvant treatment with exemestane after tamoxifen in postmenopausal women with early breast cancer. Eur J Int Med 2008 Dec; 19(8): 592–7

    Article  CAS  Google Scholar 

  23. Markopoulos C, Polychronis A, Zobolas V, et al. The effect of exemestane on the lipidemic profile of post-menopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study. Breast Cancer Res Treat 2005 Sep; 93(1): 61–6

    Article  PubMed  CAS  Google Scholar 

  24. Markopoulos C, Chrissochou M, Michailidou A, et al. Effect of exemestane on the lipidemic profile of post-menopausal operable breast cancer patients following 5–7 years of adjuvant tamoxifen: preliminary results of the ATENA sub-study. Anticancer Drugs 2005 Sep; 16(8): 879–83

    Article  PubMed  CAS  Google Scholar 

  25. Francini G, Petrioli R, Montagnani A, et al. Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids. Br J Cancer 2006 Jul 17; 95(2): 153–8

    Article  PubMed  CAS  Google Scholar 

  26. Anker GB, Refsum H, Ueland PM, et al. Influence of aromatase inhibitors on plasma total homocysteine in postmenopausal breast cancer patients. Clin Chem 1999 Feb; 45(2): 252–6

    PubMed  CAS  Google Scholar 

  27. Zilembo N, Noberasco C, Bajetta E, et al. Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor. Br J Cancer 1995; 72(4): 1007–12

    Article  PubMed  CAS  Google Scholar 

  28. Geisler J, King N, Anker G, et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 1998 Sep; 4(9): 2089–93

    PubMed  CAS  Google Scholar 

  29. Johannessen DC, Engan T, Di Salle E, et al. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin Cancer Res 1997 Jul; 3(7): 1101–8

    PubMed  CAS  Google Scholar 

  30. Atalay G, Dirix L, Biganzoli L, et al. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, ’Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients’. Ann Oncol 2004 Feb; 15(2): 211–7

    Article  PubMed  CAS  Google Scholar 

  31. Evans TR, Di Salle E, Ornati G, et al. Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res 1992 Nov 1; 52(21): 5933–9

    PubMed  CAS  Google Scholar 

  32. McClosky EV, Hannon RA, Lakner G, et al. Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. Eur J Cancer 2007 Nov; 43(17): 2523–31

    Article  Google Scholar 

  33. Geisler J, Lønning PE, Krag LE, et al. Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study. Eur J Cancer 2006 Nov; 42(17): 2968–75

    Article  PubMed  CAS  Google Scholar 

  34. Lonn E. Homocysteine in the prevention of ischemic heart disease, stroke and venous thromboembolism: therapeutic target or just another distraction? Curr Opin Hematol 2007 Sep; 14(5): 481–7

    PubMed  CAS  Google Scholar 

  35. Humphrey LL, Fu R, Rogers K, et al. Homocysteine levels and coronary heart disease incidence: a systemic review and meta-analysis. Mayo Clin Proc 2008 Nov; 83(11): 1203–12

    Article  PubMed  Google Scholar 

  36. Coleman RE, Banks LM, Girgis SI, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 2007 Feb; 8(2): 119–27

    Article  PubMed  CAS  Google Scholar 

  37. Gonnelli S, Cadirni A, Caffarelli C, et al. Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane. Bone 2007 Jan; 40(1): 205–10

    Article  PubMed  CAS  Google Scholar 

  38. Hadji P, Ziller M, Kieback DG, et al. Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised sub-study. Ann Oncol. Epub 2009 Feb 13

  39. Hadji P, Ziller M, Kieback DG, et al. The effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial. Breast Epub 2009 Apr 11

  40. Jones S, Stokoe C, Sborov M, et al. The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer. Clin Breast Cancer 2008 Dec; 8(6): 527–32

    Article  PubMed  CAS  Google Scholar 

  41. Spinelli R, Jannuzzo MG, Poggesi I, et al. Pharmacokinetics (PK) of Aromasin® (exemestane, EXE) after single and repeated doses in healthy postmenopausal volunteers (HPV) [abstract no. 1185]. Eur J Cancer 1999 Sep; 35 Suppl. 4: S295

    Article  Google Scholar 

  42. Poggesi I, Jannuzzo MG, Di Salle E, et al. Effect of food and formulation on the pharmacokinetics and pharmacodynamics of a single oral dose of exemestane (Aromasin®, EXE) [abstract no. 741]. Proc Am Soc Clin Oncol 1999; 18: 193a

    Google Scholar 

  43. Jannuzzo MG, Spinelli R, Poggesi I, et al. Inhibition of CYP3A4 does not influence Aromasin® (exemestane, EXE) pharmacokinetics (PK) in healthy postmenopausal volunteers (HPV) [abstract no. 1184]. Eur J Cancer 1999 Sep; 35 Suppl. 4: S294

    Article  Google Scholar 

  44. Jannuzzo MG, Poggesi I, Spinelli R, et al. The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women. Cancer Chemother Pharmacol 2004 Jun; 53(6): 475–81

    Article  PubMed  CAS  Google Scholar 

  45. Mayordomo J, Llombart A, Martin M, et al. Randomized, multicenter, crossover phase II trial to compare exemestane vs. anastrozole in postmenopausal patients with advanced breast cancer and positive hormone receptors. Final efficacy analysis of GEICAM 2001-03 study [abstract no. 638]. J Clin Oncol 2006 Jun 20; 24 (18 Suppl.): 37

    Article  Google Scholar 

  46. Jones SE, Seynaeve C, Hasenburg A, et al. Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer [abstract no. 15 plus presentation]. San Antonio Breast Cancer Symposium 2008 Dec 10–14; San Antonio (TX)

  47. Paridaens RJ, Dirix LY, Beex LV, et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 2008 Oct 20; 26(30): 4883–90

    Article  PubMed  CAS  Google Scholar 

  48. Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008 Apr 1; 26(10): 1664–70

    Article  PubMed  CAS  Google Scholar 

  49. Chernozemsky I, Kalinov K, Tzekov H, et al. Randomized phase III trial of exemestane or tamoxifen in first-line hormonal treatment of postmenopausal women with metastatic breast cancer [abstract no. 2101]. Breast Cancer Res Treat 2007 Dec; 106 Suppl. 1: 119

    Google Scholar 

  50. Mamounas EP, Jeong JH, Wickerham DL, et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial. J Clin Oncol 2008 Apr 20; 26(12): 1965–71

    Article  PubMed  CAS  Google Scholar 

  51. Fallowfield LJ, Bliss JM, Porter LS, et al. Quality of life in the Intergroup Exemestane Study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 2006 Feb 20; 24(6): 910–7

    Article  PubMed  CAS  Google Scholar 

  52. Fallowfield LJ, Langridge CI, Kilburn LS, et al. Quality of life in the Intergroup Exemestane Study 5 years post-randomisation [abstract no. 1091]. Breast Cancer Res Treat 2007 Dec; 106 Suppl. 1: 73. Plus poster presented at the 30th San Antonio Breast Cancer Symposium; 2007 Dec 13–17; San Antonio, (TX)

    Google Scholar 

  53. van Nes JGH, Voskuil DW, van Leeuwen FE, et al. Quality of life in relation to hormonal treatment of postmenopausal women in the Dutch Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial [abstract no. 21]. Cancer Res 2009 Jan 15; 69 (2 Suppl.): 69s

    Google Scholar 

  54. Laffaioli RV, Formato R, Tortoriello A, et al. Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer. Br J Cancer 2005; 92(9): 1621–5

    Article  Google Scholar 

  55. Thürlimann B, Paridaens R, Serin D, et al. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Eur J Cancer 1997 Oct; 33(11): 1767–73

    Article  PubMed  Google Scholar 

  56. Gennatas C, Michalaki V, Carvounis E, et al. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on letrozole or anastrozole. A phase II trial conducted by the Hellenic Group of Oncology (HELGO). Tumori 2006 Jan–Feb; 92(1): 13–7

    PubMed  CAS  Google Scholar 

  57. Jones S, Vogel C, Arkhipov A, et al. Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. J Clin Oncol 1999 Nov; 17(11): 3418–25

    PubMed  CAS  Google Scholar 

  58. Kvinnsland S, Anker G, Dirix LY, et al. High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment. Eur J Cancer 2000 May; 36(8): 976–82

    Article  PubMed  CAS  Google Scholar 

  59. Lønning PE, Bajetta E, Murray R, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 2000 Jun; 18(11): 2234–44

    PubMed  Google Scholar 

  60. Bertelli G, Garrone O, Merlano M, et al. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. Oncology 2005; 69(6): 471–7

    Article  PubMed  Google Scholar 

  61. Campos SM, Guastalla JP, Subar M, et al. A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. Clin Breast Cancer 2009 Feb; 9(1): 39–44

    Article  PubMed  CAS  Google Scholar 

  62. Chia S, Piccart M, Gradishar W, et al. Fulvestrant vs exemestane following non-steroidal aromatase inhibitor failure: first overall survival data from the EFECT trial [abstract no. 2091]. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13–16; San Antonio (TX)

  63. Paridaens R, Dirix L, Lohrisch C, et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 2003 Sep; 14(9): 1391–8

    Article  PubMed  CAS  Google Scholar 

  64. US National Institutes of Health. Providing information regarding several clinical trials that are planned/ongoing/completed [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2008 Sep 25]

  65. Jones SE, Cantrell J, Vukelja S, et al. Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy. J Clin Oncol 2007 Oct 20; 25(30): 4765–71

    Article  PubMed  CAS  Google Scholar 

  66. Gil JM, Rubio-Terrés C, Del Castillo A, et al. Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer. Clin Transl Oncol 2006 May; 8(5): 339–48

    Article  PubMed  CAS  Google Scholar 

  67. Lundkvist J, Wilking N, Holmberg S, et al. Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2–3 years treatment with tamoxifen in Sweden. Breast Cancer Res Treat 2007 May; 102(3): 289–99

    Article  PubMed  Google Scholar 

  68. Skedgel C, Rayson D, Dewar R, et al. Cost-utility of adjuvant hormone therapies for breast cancer in postmenopausal women: sequential tamoxifen-exemestane and upfront anastrozole. Breast Cancer Res Treat 2007 Mar; 101(3): 325–33

    Article  PubMed  CAS  Google Scholar 

  69. Skedgel C, Rayson D, Dewar R, et al. Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole. Breast 2007 Jun; 16(3): 252–61

    Article  PubMed  CAS  Google Scholar 

  70. Thompson D, Taylor DC, Montoya EL, et al. Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer. Value Health 2007 Sep–Oct; 10(5): 367–76

    Article  PubMed  Google Scholar 

  71. Coombes RC, Hall E, Snowdon CF, et al. The Intergroup Exemestane Study: a randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen — updated survival analysis [abstract no. 3]. Breast Cancer Res Treat 2004; 88 Suppl. 1: 7

    Google Scholar 

  72. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005 Jan; 365(9453): 60–2

    Article  PubMed  CAS  Google Scholar 

  73. Baum M, Buzdar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial [published erratum appears in Lancet 2002; 360 (9344): 152]. Lancet 2002; 359(9324): 2131–9

    Article  PubMed  CAS  Google Scholar 

  74. Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003 Nov; 98(9): 1802–10

    Article  PubMed  CAS  Google Scholar 

  75. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003 Nov 6; 349(19): 1793–802

    Article  PubMed  CAS  Google Scholar 

  76. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA. 17. J Natl Cancer Inst 2005 Sep; 97(17): 1262–71

    Article  CAS  Google Scholar 

  77. Gould RE, Garcia AA. Update on aromatase inhibitors in breast cancer. Curr Opin Obstet Gynecol 2006 Feb; 18(1): 41–6

    Article  PubMed  Google Scholar 

  78. Gradishar WJ. Tamoxifen: what next? Oncologist 2004; 9(4): 378–84

    Article  PubMed  CAS  Google Scholar 

  79. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer 2009 [online]. Available from URL: http://misc.medscape.com/images/586/406/Breast-Medscape.pdf [Accessed 2009 Apr 28]

  80. Thorne C. Management of arthralgias associated with aromatase inhibitor therapy. Curr Oncol 2007 Dec; 14 Suppl. 1: S11–9

    Article  PubMed  Google Scholar 

  81. Buzdar AU, Coombes RC, Goss PE, et al. Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. Cancer 2008 Dec; 112 Suppl. 3: 700–9

    Article  Google Scholar 

  82. Wheler J, Johnson M, Seidman A. Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy. Semin Oncol 2006 Dec; 33(6): 672–80

    Article  PubMed  CAS  Google Scholar 

  83. Pestalozzi B, Castiglione M. Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008 May; 19 Suppl. 2: ii7–10

    Article  PubMed  Google Scholar 

  84. Goldhirsch A, Wood WC, Gelber RD, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007 Jul; 18(7): 1133–44

    Article  PubMed  CAS  Google Scholar 

  85. Sanford M, Plosker GL. Anastrozole: a review of its use in postmenopausal women with early-stage breast cancer. Drugs 2008; 68(9): 1319–40

    Article  PubMed  CAS  Google Scholar 

  86. AstraZeneca UK Ltd. Arimidex® 1 mg film-coated tablets: summary of product characteristics [online]. Available from URL: http://www.emc.medicines.org.uk [Accessed 2009 Apr 28]

  87. Mouridsen HT, Giobbie-Hurder A, Mauriac L, et al. BIG 1-98: a randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer [abstract no. 13]. Cancer Res 69 (2 Suppl.): 66s

  88. Novartis Pharmaceuticals UK Ltd. Femara® 2.5mg tablets: summary of product characteristics [online]. Available from URL: http://www.emc.medicines.org.uk [Accessed 2009 Apr 28]

  89. AstraZeneca Pharmaceuticals LP. Arimidex® (anastrozole) tablets: US prescribing information [online]. Available from URL: http://www.fda.gov/cder/foi/label/2008/020541s020s021s023lbl.pdf [Accessed 2009 Mar 13]

  90. Novartis Pharmaceuticals Corporation. Femara® (letrozole) 2.5mg tablets: US prescribing information [online]. Available from URL: http://www.fda.gov/cder/foi/label/2007/020726s014lbl.pdf [Accessed 2008 Sep 22]

  91. Kataja V, Catiglione M. Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008 May; 19 Suppl. 2: ii11–3

    Article  PubMed  Google Scholar 

  92. National Breast and Ovarian Cancer Centre. Recommendations for use of endocrine therapy for the treatment of hormone receptor-positive advanced breast cancer [online]. Available from URL: http://www.nbocc.org.au/bestpractice/resources/ETAG_recommendationsforus.pdf [Accessed 2008 Sep 25]

  93. Goss PE, Strasser K. Tamoxifen resistant and refractory breast cancer. The value of aromatase inhibitors. Drugs 2002; 62(6): 957–66

    CAS  Google Scholar 

  94. Lønning PE. Is there a growing role for endocrine therapy in the treatment of breast cancer? Drugs 2000 Jul; 60(1): 11–21

    Article  PubMed  Google Scholar 

  95. Carlini P, Bria E, Giannarelli D, et al. New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials. Cancer 2005 Oct 1; 104(7): 1335–42

    Article  PubMed  CAS  Google Scholar 

  96. AstraZeneca UK Ltd. Faslodex: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/faslodex/H-540-PI-en.pdf [Accessed 2009 Mar 13]

  97. AstraZeneca Pharmaceuticals LP. Faslodex (fulvestrant) injection: US prescribing information [online]. Available from URL: http://www.fda.gov/cder/foi/label/2005/021344s004lbl.pdf [Accessed 2008 Sep 26]

  98. Perez EA. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann Oncol 2007; 18 Suppl. 8: viii26–35

    Article  PubMed  Google Scholar 

  99. Conte P, Frassoldati A. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: putting safety issues into perspective. Breast J 2007 Jan–Feb; 13(1): 28–35

    Article  PubMed  CAS  Google Scholar 

  100. Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007 Mar 1; 25(7): 829–36

    Article  PubMed  CAS  Google Scholar 

  101. Lønning PE. Exemestane for breast cancer prevention: a feasible strategy? Clin Cancer Res 2005 Jan 15; 11 (2 Pt 2): 918–24s

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Emma D. Deeks.

Additional information

Various sections of the manuscript reviewed by: A.U. Buzdar, Department of Breast Medical Oncology, M. D. Anderson Cancer Center, University of Texas, Houston, Texas, USA; P. Carlini, Department of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy; S. Gonnelli, Department of Internal Medicine, University of Siena, Siena, Italy; P.E. Lønning, Institute of Medicine, University of Bergen, and Department of Oncology, Haukeland University Hospital, Bergen, Norway.

Data Selection

Sources: Medical literature published in any language since 1980 on ‘exemestane’, identified using MEDLINE and EMBASE, supplemented by AdisBase (a proprietary database of Wolters Kluwer Health | Adis). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug.

Search strategy: MEDLINE, EMBASE and AdisBase search terms were ‘exemestane’ and (‘early breast cancer’ or ‘early-stage breast cancer’ or ‘advanced breast cancer’). Searches were last updated 21 April 2009.

Selection: Studies in patients with breast cancer who received exemestane. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included.

Index terms: Exemestane, aromatase inhibitors, breast cancer, postmenopausal, pharmacodynamics, pharmacokinetics, therapeutic use, tolerability, pharmacoeconomics.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Deeks, E.D., Scott, L.J. Exemestane. Drugs 69, 889–918 (2009). https://doi.org/10.2165/00003495-200969070-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200969070-00007

Keywords

Navigation